SCHEMBL4092648

SCHEMBL4092648

O=C(Nc1cccc(S(=O)(=O)CC2CC2)c1)NC(c1ccc(C(=O)Nc2nn[nH]n2)cc1)c1ccc(C2CCCCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCGR P47871 8/20 0.43
LMNA P02545 1/20 0.41
NAMPT P43490 1/20 0.37
GIPR P48546 2/20 0.37
KIF18A Q8NI77 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
SIRT3 Q9NTG7 1/20 0.36
CCKBR P32239 2/20 0.36
HDAC3 O15379 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
DEGS1 O15121 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4092780 0.93 GCGR (0.46) GCGRLMNANAMPTGIPRSIRT2
SCHEMBL4085175 0.90 GCGR (0.43) GCGRLMNANAMPTGIPRSIRT2
SCHEMBL4088312 0.89 LMNA (0.42) GCGRLMNANAMPTGIPRKIF18A
SCHEMBL4095065 0.88 GCGR (0.44) GCGRLMNANAMPTGIPRSIRT2
SCHEMBL4091977 0.88 GCGR (0.44) GCGRLMNAMEN1ALDH1A1POLB
SCHEMBL4091639 0.87 LMNA (0.56) LMNAMEN1ALDH1A1KMT2A
SCHEMBL4085772 0.86 MAPT (0.45) GCGRLMNASIRT2MEN1ALDH1A1
SCHEMBL4087662 0.85 GCGR (0.46) GCGRLMNANAMPTGIPRCCKBR
SCHEMBL4092326 0.85 LMNA (0.45) GCGRLMNANAMPTGIPRHDAC3
SCHEMBL4086811 0.85 GCGR (0.42) GCGRLMNANAMPTGIPRSIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885LMNA 3643/4885NAMPT 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.